In addition to heartburn, how many of your patients with nonerosive GERD present with associated symptoms, such as regurgitation, belching and early satiety?
Get more information
on GERD
Helpful links to online
publications
You could be missing out! Become a registered member today.
GERD, or gastroesophageal reflux disease, occurs when stomach acid frequently refluxes back into the esophagus. According to the Montreal definition, GERD is defined as a condition that develops when the reflux of stomach contents causes troublesome symptoms and/or complications.1
In adults (≥18 years of age), ACIPHEX 20 mg is indicated for: treatment of daytime and nighttime heartburn and other symptoms associated with GERD; short-term, up to 4 weeks, treatment in the healing and symptomatic relief of duodenal ulcers; short-term, 4 to 8 weeks, treatment in the healing and symptomatic relief of erosive GERD; and maintenance of healing and reduction in relapse rates of heartburn symptoms or erosive GERD (controlled maintenance studies do not extend beyond 12 months).
In adolescent patients 12 years of age and above, ACIPHEX 20 mg is indicated for: short-term, up to 8 weeks, treatment of daytime and nighttime heartburn and other symptoms associated with GERD.
ACIPHEX is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or to any component of the formulation.
As with all PPIs, patients treated concomitantly with warfarin may need to be monitored for increases in INR and prothrombin time, which may lead to abnormal bleeding and even death.
In adolescents, the related reported adverse reactions that occurred in ≥2% of patients were headache and nausea. The adverse reactions reported without regard to relationship to ACIPHEX that occurred in ≥2% of patients were headache, diarrhea, nausea, vomiting, and abdominal pain.
In adults, clinical trials revealed the following adverse reactions appearing in ≥2% of ACIPHEX patients and with a frequency greater than placebo: pain, pharyngitis, flatulence, infection, and constipation.
Symptomatic response to therapy does not preclude the presence of gastric malignancy.
ACIPHEX inhibits gastric acid secretion and may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g., ketoconazole, iron salts and digoxin).
ACIPHEX may reduce the plasma levels of atazanavir.
Rabeprazole has been shown to inhibit cyclosporine metabolism in vitro.
References: 1. Vakil N, Van Zanten SV, Kahrilas P, Dent J, Jones R, and the Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920. 2. American College of Gastroenterology Web site. http://www.acg.gi.org/patients/gerd/word.asp. Accessed June 6, 2008. 3. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systemic review. Gut. 2005;54:710-717. 4. Eisen GM, Sandler RS, Murray S, Gottfried M. The relationship between gastroesophageal reflux disease and its complications with Barrett’s esophagus. Am J Gastroenterol. 1997;92:27-31. 5. Scott M, Gelhot AR. Gastroesophageal reflux disease: diagnosis and management. Am Fam Physician. 1999;59:1181-1189.
©2010 Eisai Inc. and Ortho-McNeil Janssen Pharmaceuticals, Inc. This site originates in the United States.
This information is intended for use by healthcare professionals in the United States only. Eisai Inc. and PriCara®, Division of Ortho-McNeil Janssen Pharmaceuticals, Inc., recognize that the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States.
This site contains information about products that may have different product labeling in different countries. This site is intended for adults 18 years and older.
This site is published by Eisai Inc. and PriCara®, which are solely responsible for its contents.
ACIPHEX is a registered trademark of Eisai Company, Ltd.
This site was last modified on: [Jan 04 2010 at 10:29:42 EST EDT]